Archives
What the Rabbit Pharming Comparison Really Shows
2026-11-22
A targeted rabbit CSN2 knock-in produced a striking tdTomato milk-expression result, but the evidence supports a locus-specific proof of concept rather than a general prediction for therapeutic proteins or a role for HEPES.
The NHE1–Olfr2 Axis in Atherosclerosis
2026-11-21
A 2025 mouse-and-macrophage study links octanal–Olfr2 signaling to NHE1 activation, calcium-associated oxidative stress, inflammasome responses, foam-cell formation and atherosclerotic lesions. Western blot reagents support measurement of these molecular changes, but they are analytical tools rather than causes of the biological phenotype.
Targeted Rabbit Pharming: What the Evidence Shows
2026-11-20
A 2025 study provides a strong proof of concept for directing reporter-protein expression to the rabbit CSN2 milk-protein locus. Its 15–20 g/L result is notable, but the limited number of animals, reporter-only design, and heterogeneous historical comparisons constrain claims about therapeutic manufacturing.
PET Imaging of mRNA Antigen Expression In Vivo
2026-11-19
A reporter-based PET strategy connected translation of tagged mRNA vaccine antigen to whole-body spatiotemporal imaging in female mice and male non-human primates. The approach separates protein expression from carrier or RNA biodistribution, while remaining bounded by reporter biology, tracer kinetics, animal models, and the distinction between expression and vaccine efficacy.
How NHE1 Links Octanal to Macrophage Atherosclerosis
2026-11-19
A 2025 study used mouse and macrophage models to examine how octanal-associated Olfr2 signaling engages NHE1, calcium, reactive oxygen species, and NLRP3-related inflammation. The evidence supports NHE1 as a mechanistic mediator of plaque-associated responses, while model choice, pathway-ordering uncertainties, and limited sample sizes constrain translation to human disease.
HEPES and the Limits of a Rabbit Pharming Result
2026-11-18
HEPES is a pH-buffering chemical, whereas the reported rabbit pharming result primarily tests a genetic locus-and-promoter strategy. The study found 15–20 g/L of the reporter tdTomato in milk from two homozygous females, but this does not establish a HEPES effect, therapeutic-protein equivalence, or a universal production benchmark.
When Context Changes a Biological Result
2026-11-18
A 15–20 g/L reporter concentration in rabbit milk is a striking proof of concept, but its meaning depends on the promoter, genomic locus, genotype, protein identity, tissue, and comparator. The study supports a locus-specific expression hypothesis—not evidence that HEPES caused the outcome or that the result generalizes directly to therapeutic manufacturing.
NHE1 Links Octanal Signaling to Atherosclerosis
2026-11-17
A mouse-and-macrophage study supports a mechanistic model in which octanal/Olfr2 signaling engages NHE1 and is associated with calcium-, ROS-, lipid-accumulation, and inflammasome-related responses. Pharmacologic inhibition and genetic reduction of NHE1 attenuated several findings, while the precise ordering of calcium and ROS events remains unresolved.
Targeted CSN2 Knock-In in Rabbit Pharming
2026-11-17
A 2025 study used a targeted CSN2-locus strategy to create heritable rabbit expression of the fluorescent reporter tdTomato in milk. The reported 15–20 g/L concentration in milk from two homozygous females is a striking proof of concept for locus- and promoter-directed expression, but it does not establish equivalent performance for therapeutic proteins, general manufacturing output, or HEPES-related mechanisms.
What the CSN2 Rabbit Pharming Study Shows
2026-11-16
A 2025 study used targeted insertion at the rabbit CSN2 milk-protein locus to test whether endogenous regulatory control could improve recombinant protein production. Its 15–20 g/L tdTomato result is a strong proof of concept, but the evidence remains limited to a reporter protein, a small number of homozygous animals, and a concentration readout rather than therapeutic-product performance.
HEPES and the Limits of Rabbit Pharming Evidence
2026-11-16
A 2025 study reported unusually high tdTomato concentrations after targeted insertion at the rabbit CSN2 milk-protein locus. The result supports a locus-and-promoter mechanism, not a demonstrated role for HEPES, and its relevance to therapeutic proteins remains unproven.
NHE1 and Octanal Signaling in Atherosclerosis
2026-11-15
A mouse-and-macrophage study examines whether octanal/Olfr2 signaling promotes atherosclerotic and inflammatory phenotypes through NHE1. Convergent pharmacologic, genetic, and knockdown evidence supports a pathway involving altered pH regulation, calcium-associated signaling, oxidative responses, and NLRP3-linked inflammation, while the causal ordering of these events remains unresolved.
Targeted CSN2 Insertion in Rabbit Milk
2026-11-14
A proof-of-concept rabbit study tested whether placing a tdTomato reporter at the endogenous CSN2 locus could couple recombinant-protein expression to the native β-casein regulatory system. The reported results support heritable expression and higher reporter abundance in homozygous animals, while remaining preliminary because the model used a reporter rather than a therapeutic protein and the milk comparison involved few animals.
Targeted Rabbit CSN2 Expression and Milk Yield
2026-11-13
A proof-of-concept rabbit study examined whether placing a tdTomato reporter within the endogenous CSN2 locus could couple recombinant-protein expression to the native β-casein regulatory context. The work reported germline transmission and higher reporter concentrations in homozygous animals, while leaving therapeutic-protein performance and direct comparisons with conventional transgenesis unresolved.
When Context Changes a CAR-T Result
2026-11-13
A preclinical NSCLC study illustrates why antigen distribution, comparator choice, model design, and measurement modality determine what a CAR-T result can support. The associated chemiluminescent reagent belongs to the protein-detection layer and should not be confused with evidence for therapeutic efficacy.